Partnerships for antibody and vaccine candidates.

We study a new class of antibacterial and antiviral substances.

Phase 1 - 6,000,000 vials per 24 hours.

17,500L Bioreactors CIP/SIP

Phase 2 - Add 9,000,000 vials per 24 hours. Total: 15m per 24 hours. Includes integrated robotics and advanced-automation.

Clinical trials in the USA, India and Italy.